Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.
Sign Up to like & getrecommendations! Published in 2019 at "Blood advances"
DOI: 10.1182/bloodadvances.2019031336
Abstract: This phase 2 study was conducted to prospectively evaluate how clinical and biological factors correlate with outcome in patients with treatment-naive (TN) and relapsed (R) chronic lymphocytic leukemia (CLL) treated with lenalidomide and rituximab. Oral… read more here.
Keywords: cll; patients treatment; lenalidomide rituximab; naive relapsed ... See more keywords
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2023009992
Abstract: Mantle cell lymphoma (MCL) is a rare, incurable hematological malignancy with a heterogenous presentation and clinical course. A wide variety of chemotherapy-based regimens are currently utilized in untreated patients. Several targeted or small molecule therapies… read more here.
Keywords: adding venetoclax; cell lymphoma; patients untreated; mantle cell ... See more keywords